Search clinical trials for: AMR101

Total 199 results

Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
University of Cincinnati
United States Department of Defense

Recruiting

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

Meniscus Tear

United States
Aurigene Discovery Technologies Limited

Completed

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) (INDUS-3)

Plaque Psoriasis

United States
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
Aurigene Discovery Technologies Limited

Completed

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (INDUS-2)

Chronic Plaque-type Psoriasis

India
Aurigene Discovery Technologies Limited

Recruiting

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) (ASHA-1)

Relapsed Advanced Lymphomas

India
Aimmune Therapeutics, Inc.

Completed

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Peanut Allergy

United States, Canada, Spain, Netherlands, Germany, United Kingdom, Ireland, Sweden, France, Italy
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

United States, Korea, Republic of
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
Hugel

Completed

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

Hypertrophic Scar

Korea, Republic of
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Amarin Pharma Inc.

Completed

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)

Hypertriglyceridemia

United States
Aurigene Discovery Technologies Limited

Recruiting

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (JIVAN)

Kidney Cancer | Gastric Cancer | Non Small Cell Lung Cancer | Colon Cancer | Urothelial Carcinoma | Relapse | Esophagus Cancer | Advanced Malignant Neoplasm

India
Novartis Pharmaceuticals

Withdrawn

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. (MACS1881)

Chronic Myeloid Leukemia (CML)

Brazil
Amicus Therapeutics

Terminated

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Type 1 Gaucher Disease

United States, United Kingdom
Aurigene Discovery Technologies Limited

Recruiting

First in Human, Dose Escalation, Dose Expansion Study of AUR105 (SURYA-1)

Hodgkin Lymphoma | Solid Tumor, Adult | Non-hodgkin Lymphoma

India
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Hugel

Terminated

the Hypertrophic Scar Prevention of BMT101.

Hypertrophic Scar

Korea, Republic of
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (ARC001)

Peanut Allergy

United States
Peking Union Medical College Hospital
Stanford University

Unknown

68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China
Massachusetts General Hospital
National Institutes of Health (NIH)

Completed

PRevention Using EPA Against coloREctal Cancer (PREPARE)

Colorectal Cancer | Colorectal Adenoma | Gastrointestinal Microbiome | Endoscopic Surgery | Eicosapentaenoic Acid

United States
Marea Therapeutics

Recruiting

Study of MAR001 in Adults With Metabolic Dysfunction

Hypertriglyceridemia

Australia
Novartis Pharmaceuticals

Completed

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Medical College of Wisconsin
National Institute on Aging (NIA)

Completed

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

APOE 4

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
Future Medicine
Futuremedicine Australia

Recruiting

FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension

Ocular Hypertension

Australia
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Bionovo

Completed

Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes

Hot Flashes

United States
Allecra

Completed

Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers

Healthy

United States
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD (Nilo-cGVHD)

Chronic Graft Versus Host Disease

Israel, Italy
CANbridge Life Sciences Ltd.

Recruiting

Phase 2 Study of CAN008 in Subjects With GBM

Newly-diagnosed Glioblastoma

China
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Chronic Myelogenous Leukemia

Turkey
Stanford University
Novartis

Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant Failure

United States, Canada
Rony Schaffel

Terminated

Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALLPhi)

Acute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
M.D. Anderson Cancer Center
Novartis

Withdrawn

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Cancer
Aimmune Therapeutics, Inc.

Completed

ARTEMIS Peanut Allergy In Children (ARTEMIS)

Peanut Allergy

United Kingdom, Italy, France, Germany, Ireland, Spain, Sweden
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Future Medicine

Completed

A SAD, MAD, and FE Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of FM101 in Healthy Volunteers

Healthy Subjects

Netherlands
Apogenix GmbH

Completed

APG101 in Glioblastoma

Glioblastoma Multiforme

Austria, Germany
Alladapt Immunotherapeutics, Inc.

Completed

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Food Allergy

United States
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Bionovo

Completed

Sleep Quality in CHIMES (MF101)

Sleep Quality | Menopausal Symptoms

United States
Bionovo

Terminated

Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components

Healthy

United States

Search clinical trials for: AMR101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations